Cargando…

The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab

Bullous pemphigoid (BP) is a rare autoimmune blistering condition that predominantly affects the elderly population. Typical treatment regimens target the immune system and inflammatory response. We present a case of BP in a 78-year-old male patient that occurred following the coronavirus disease 20...

Descripción completa

Detalles Bibliográficos
Autores principales:	Savoldy, Michelle A, Tadicherla, Teja, Moureiden, Zade, Ayoubi, Noura, Baldwin, Brooke T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Dermatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675981/ https://www.ncbi.nlm.nih.gov/pubmed/36415388 http://dx.doi.org/10.7759/cureus.30541

Ejemplares similares

When Bullous Pemphigoid Is Not Bullous Pemphigoid: The Importance of Going Beyond Direct Immunofluorescence
por: Hopkins, Christina R, et al.
Publicado: (2022)

Hydrochlorothiazide vs Venlafaxine: Drug-induced Bullous Pemphigoid
por: Naramala, Srikanth, et al.
Publicado: (2019)

Dyshidrosiform Bullous Pemphigoid Triggered by COVID-19 Vaccination
por: Shanshal, Mohammed
Publicado: (2022)

Combination Therapy of Plasma Exchange and Rituximab to Treat Cicatricial Pemphigoid and Bullous Pemphigoid
por: Kunadia, Anuj, et al.
Publicado: (2021)

Dyshidrosiform Bullous Pemphigoid: Case Reports and Review
por: Cohen, Philip R
Publicado: (2020)

Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab
por: Olsen, Eric, et al.
Publicado: (2023)

A Case of Drug-Induced Bullous Pemphigoid With an Isomorphic Response and Updated Review of Koebnerization in Bullous Diseases
por: Ambur, Austin B, et al.
Publicado: (2021)

A Case of Bullous Pemphigoid Associated With Nivolumab Therapy
por: Gotera, Nico, et al.
Publicado: (2022)

A Case of Severe Bullous Dermatitis With Mixed Bullous Pemphigoid and Pemphigus Vulgaris Cutaneous Manifestations
por: Burns, Reece D, et al.
Publicado: (2021)

Bullous Pemphigoid Following the Moderna mRNA-1273 Vaccine
por: Desai, Amar D, et al.
Publicado: (2022)

Case report: Successful treatment of non-bullous lichen planus pemphigoides with dupilumab
por: Li, Si-Zhe, et al.
Publicado: (2022)

Successful Treatment of Psoriasis Combined with Bullous Pemphigoid with Dupilumab: A Case Report
por: Liu, Jing-Hua, et al.
Publicado: (2023)

A Case of Bullous Pemphigoid: A Prevalent and Potentially Fatal Condition
por: Parellada, Jorge, et al.
Publicado: (2018)

Bullous Pemphigoid in a Centenarian Male Simulating Toxic Epidermal Necrolysis
por: Shakhashiro, Muna, et al.
Publicado: (2023)

Dupilumab for the treatment of pembrolizumab‐induced bullous pemphigoid: A case report
por: Pop, Samantha R., et al.
Publicado: (2022)

Bullous Pemphigoid: A Spontaneous Presentation in a Patient With Chronic Kidney Disease
por: Brazen, Brett, et al.
Publicado: (2022)

Association of Bullous Pemphigoid with Malignancy: A Myth or Reality?
por: Fernandes, Joycelin, et al.
Publicado: (2014)

Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid
por: Chen, Fangyuan, et al.
Publicado: (2023)

Bullous Pemphigoid and Human Leukocyte Antigen (HLA)-DQA1: A Systematic Review
por: Hesari, Roksana, et al.
Publicado: (2023)

Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
por: Zhang, Yihua, et al.
Publicado: (2021)

Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?
por: Russo, Roberto, et al.
Publicado: (2022)

Recalcitrant bullous pemphigoid responsive to dupilumab in an adolescent patient
por: Zhou, Albert E., et al.
Publicado: (2022)

Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid
por: WANG, Qijun, et al.
Publicado: (2023)

A Rare Case of Bullous Pemphigoid Secondary to Checkpoint Inhibitor Immunotherapy: A Tense Situation
por: Wesolow, Jacqueline T, et al.
Publicado: (2021)

A Case of Bullous Pemphigoid in a Five-Month-Old Female: A Rare Presentation
por: Ahmed, Mohamed, et al.
Publicado: (2023)

Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid
por: Manzo Margiotta, Flavia, et al.
Publicado: (2023)

Bullous Pemphigoid Associated With Pembrolizumab Therapy for Non-Small-Cell Lung Cancer: A Case Report
por: Chatterjee, Tulika, et al.
Publicado: (2022)

Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
por: Wang, Si-Hang, et al.
Publicado: (2021)

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid
por: Seyed Jafari, S. Morteza, et al.
Publicado: (2021)

Validation study of bullous pemphigoid and pemphigus vulgaris recording in routinely collected electronic primary healthcare records in England
por: Persson, Monica S M, et al.
Publicado: (2020)

Bullous Pemphigoid Limited to the Hands and Feet: A Rare Case of an Infantile Disease Pattern Seen in an Elderly Patient
por: Nellore, Aditya, et al.
Publicado: (2023)

Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review
por: Cao, Peng, et al.
Publicado: (2022)

Successful treatment of Brunsting-Perry pemphigoid with dupilumab
por: Blum, Franklin R., et al.
Publicado: (2021)

Severe pemphigoid nodularis successfully treated with dupilumab
por: Jendoubi, Fatma, et al.
Publicado: (2022)

Lichen planus pemphigoides successfully treated with dupilumab
por: Ch’en, Peter Yi, et al.
Publicado: (2022)

Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types
por: Yan, Tianmeng, et al.
Publicado: (2023)

Bullous Pilomatrixoma After COVID-19 Vaccination
por: Alvarez-Rubio, Francisco Javier, et al.
Publicado: (2022)

Bullous pemphigoid
por: Miyamoto, Denise, et al.
Publicado: (2019)

A Rare Case of Delayed Hypersensitivity Following COVID-19 Booster Necessitating Treatment With Dupilumab
por: Hanoodi, Maryam, et al.
Publicado: (2023)

Bullous Iodide Rash
Publicado: (1909)

Cannot write session to /tmp/vufind_sessions/sess_plmmimlrj187hjtpi0tri5r81m